Travelers Indemnity Co. v. Cephalon, Inc., 620 F. App'x 82

Plaintiffs are several workers’ compensation insurers who paid >$18 million for prescriptions of Actiq and Fentora and sued Cephalon (and Teva defendants, but claims against Teva were waived on appeal) for intentional and negligent misrepresentation, CUTPA violations, unjust enrichment, and seeking injunctive relief.
Actiq and Fentora are FDA-approved for opioid-tolerant cancer patients; plaintiffs allege Cephalon promoted off-label uses and made misleading statements to physicians, causing improper prescriptions to plaintiffs’ claimants.
Plaintiffs identified certain physicians who prescribed the drugs and alleged those physicians received payments or attended Cephalon-sponsored events; plaintiffs did not allege any claimant or physician actually heard, relied on, or saw specific fraudulent statements.
The District Court dismissed the amended complaint for lack of standing (Rule 12(b)(1)) and for failure to state a claim (Rule 12(b)(6)); plaintiffs moved under Rule 59(e) for leave to file a proposed second amended complaint (SAC), which the District Court denied as futile.
On appeal, the Third Circuit affirmed: (1) fraud-based claims failed Rule 9(b) because plaintiffs did not plead specific misrepresentations, who made them, when, or to whom; (2) CUTPA claims failed for lack of proximate causation (no alleged physician reliance); and (3) amendment would be futile because the SAC still did not cure causation defects.

Issue	Plaintiff's Argument	Defendant's Argument	Held
Whether fraud-based claims satisfy Rule 9(b) particularity	Cephalon’s off-label promotion and misleading marketing were inherently fraudulent and sufficient	Plaintiffs failed to identify specific statements, omissions, recipients, timing, or reliance as Rule 9(b) requires	Dismissed: Plaintiffs failed Rule 9(b); fraud claims not pled with required particularity
Whether CUTPA claims plead causation/proximate cause	Cephalon’s deceptive marketing caused prescriptions and economic injury to insurers	Plaintiffs did not allege physicians relied on Cephalon’s statements or that prescriptions would not have been written absent marketing	Dismissed: CUTPA claims fail for lack of proximate causation
Whether plaintiffs had standing under other states’ consumer-protection laws	Plaintiffs argued injury existed but focused on Connecticut	Defendants noted plaintiffs pleaded economic injury only for Connecticut; other-state claims not argued on appeal	Court did not reach other-state laws; treated CUTPA as sole consumer-protection claim on record
Whether leave to amend (SAC) should be allowed or was futile	Proposed SAC added conference/attendance details to show causation	Defendants argued SAC still fails to show reliance or causal link between marketing and prescriptions	Denied: Amendment futile because SAC still fails to plead causation/reliance

In re Schering Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235 (3d Cir.) (off-label promotion vs. FDCA limitations)
Frederico v. Home Depot, 507 F.3d 188 (3d Cir.) (Rule 9(b) heightened particularity for fraud-based claims)
Lum v. Bank of Am., 361 F.3d 217 (3d Cir.) (must plead who made misrepresentation, to whom, and content)
Bell Atl. Corp. v. Twombly, 550 U.S. 544 (pleading standards under Rule 8 inform sufficiency review)
Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341 (FDCA does not create private causes of action and practice of medicine not governed by FDCA)
Gile v. Optical Radiation Corp., 22 F.3d 540 (3d Cir.) (violations of FDCA do not create private rights of action)
In re Westinghouse Sec. Litig., 90 F.3d 696 (3d Cir.) (fraud-sounding claims must satisfy Rule 9(b))
In re Burlington Coat Factory Sec. Litig., 114 F.3d 1410 (3d Cir.) (denial of leave to amend may be based on futility)
Stevenson Lumber Co.-Suffield v. Chase Assocs., 932 A.2d 401 (Conn.) (CUTPA requires proximate cause between defendant’s act and plaintiff’s injury)